Angiogenesis as a Therapeutic Target in Malignant Gliomas

被引:91
作者
Chi, Andrew S. [1 ,4 ]
Sorensen, A. Gregory [2 ,4 ]
Jain, Rakesh K. [3 ,4 ]
Batchelor, Tracy T. [1 ,4 ]
机构
[1] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Ctr Canc, Div Hematol & Oncol,Dept Neurol, Boston, MA 02114 USA
[2] AA Martinos Ctr Biomed Imaging, Boston, MA USA
[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
关键词
Malignant glioma; Glioblastoma; Angiogenesis; Vascular endothelial growth factor; Cerebral edema; ENDOTHELIAL-GROWTH-FACTOR; PHASE-II TRIAL; NEWLY-DIAGNOSED GLIOBLASTOMA; BEVACIZUMAB PLUS IRINOTECAN; LOW-DOSE CHEMOTHERAPY; INHIBITS TUMOR-GROWTH; HIGH-GRADE GLIOMAS; RADIATION-THERAPY; ANTIANGIOGENIC THERAPY; IMATINIB MESYLATE;
D O I
10.1634/theoncologist.2008-0272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional cytotoxic treatments. Because GBMs are highly angiogenic tumors, inhibitors that target tumor vasculature are considered promising therapeutic agents in these patients. Encouraging efficacy and tolerability in preliminary clinical trials suggest that targeting angiogenesis may be an effective therapeutic strategy in GBM patients. However, the survival benefits observed to date in uncontrolled trials of antiangiogenic agents have been modest, and several obstacles have limited their effectiveness. This article reviews the rationale for antiangiogenic agents in GBM, their potential mechanisms of action, and their clinical development in GBM patients. Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients. The Oncologist 2009; 14: 621-636
引用
收藏
页码:621 / 636
页数:16
相关论文
共 177 条
[1]   Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes [J].
Aghi, Manish ;
Cohen, Kenneth S. ;
Klein, Rachael J. ;
Scadden, David T. ;
Chioccra, E. Antonio .
CANCER RESEARCH, 2006, 66 (18) :9054-9064
[2]   Integrins in angiogenesis and lymphangiogenesis [J].
Avraamides, Christie J. ;
Garmy-Susini, Barbara ;
Varner, Judith A. .
NATURE REVIEWS CANCER, 2008, 8 (08) :604-617
[3]   Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor [J].
Bao, Shideng ;
Wu, Qiulian ;
Sathornsumetee, Sith ;
Hao, Yueling ;
Li, Zhizhong ;
Hjelmeland, Anita B. ;
Shi, Oing ;
McLendon, Roger E. ;
Bigner, Darell D. ;
Rich, Jeremy N. .
CANCER RESEARCH, 2006, 66 (16) :7843-7848
[4]   MRI of tumor angiogenesis [J].
Barrett, Tristan ;
Brechbiel, Martin ;
Bernardo, Marcelino ;
Choyke, Peter L. .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2007, 26 (02) :235-249
[5]  
BATCHELOR T, 2008, 2008 AM ASS CANC RES
[6]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[7]   Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme [J].
Baumann, F ;
Bjeljac, M ;
Kollias, SS ;
Baumert, BG ;
Brandner, S ;
Rousson, V ;
Yonekawa, Y ;
Bernays, RL .
JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) :191-200
[8]  
Bello L, 2001, CANCER RES, V61, P7501
[9]   Expression of Dll4 during mouse embryogenesis suggests multiple developmental roles [J].
Benedito, R ;
Duarte, A .
GENE EXPRESSION PATTERNS, 2005, 5 (06) :750-755
[10]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603